Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Silk Road Medical's share price for the quarter that ended in Dec. 2023 was $12.27. Silk Road Medical's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 39.2 Mil. Therefore, Silk Road Medical's market cap for the quarter that ended in Dec. 2023 was $480.6 Mil.
Silk Road Medical's quarterly market cap
declined
from Jun. 2023 ($1,261.0 Mil) to Sep. 2023 ($583.2 Mil) and
declined
from Sep. 2023 ($583.2 Mil) to Dec. 2023 ($480.6 Mil).
Silk Road Medical's annual market cap
increased
from Dec. 2021 ($1,490.5 Mil) to Dec. 2022 ($2,027.1 Mil) but then
declined
from Dec. 2022 ($2,027.1 Mil) to Dec. 2023 ($480.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Silk Road Medical's Enterprise Value for Today is $587.3 Mil.
Silk Road Medical Market Cap Historical Data
The historical data trend for Silk Road Medical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Silk Road Medical's Market Cap
For the Medical Devices subindustry, Silk Road Medical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Market Cap distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's Market Cap falls into.
Silk Road Medical Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Silk Road Medical's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silk Road Medical (NAS:SILK) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Silk Road Medical Market Cap Related Terms
Thank you for viewing the detailed overview of Silk Road Medical's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Silk Road Medical (Silk Road Medical) Business Description
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILK has been successfully added to your 